Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi Mizuma

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Journal of Pharmaceutical Sciences|July 23, 2009
Kinetic assessment of luminal degradation of orally effective prodrugs for rational drug developmentTakashi Mizuma
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|September 15, 2009
Impact of intestinal metabolism on drug developmentTakashi Mizuma
Drug Metabolism and Pharmacokinetics|December 25, 2004
Kinetic impact of presystemic intestinal metabolism on drug absorption: experiment and data analysis for the prediction of in vivo absorption from in vitro dataTakashi Mizuma
International Journal of Pharmaceutics|June 3, 2009
Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10Takashi Mizuma
Journal of Pharmaceutical Sciences|April 3, 2008
Assessment of presystemic and systemic intestinal availability of orally administered drugs using in vitro and in vivo data in humans: intestinal sulfation metabolism impacts presystemic availability much more than systemic availability of salbutamol, SULT1A3 substrateTakashi Mizuma
Journal of Pharmaceutical Sciences|August 6, 2004
Dietary polyphenols (-)-epicatechin and chrysin inhibit intestinal glucuronidation metabolism to increase drug absorptionTakashi Mizuma, Shoji Awazu
Biological Procedures Online|May 8, 2003
The Metabolic Inhibition Model Which Predicts the Intestinal Absorbability and Metabolizability of Drug: Theory and ExperimentTakashi Mizuma, Shoji Awazu
The Journal of Pharmacy and Pharmacology|May 20, 2005
Kinetic characterization of glycosidase activity from disaccharide conjugate to monosaccharide conjugate in Caco-2 cellsTakashi Mizuma, Norihiko Fuseda, Masahiro Hayashi
Biological & Pharmaceutical Bulletin|November 6, 2003
Concentration-dependent atypical intestinal absorption of cyclic phenylalanylserine: small intestine acts as an interface between the body and ingested compoundsTakashi Mizuma, Takuo Narasaka, Shoji Awazu
The Journal of Pharmacy and Pharmacology|October 3, 2002
Uptake of cyclic dipeptide by PEPT1 in Caco-2 cells: phenolic hydroxyl group of substrate enhances affinity for PEPT1Takashi Mizuma, Takuo Narasaka, Shoji Awazu
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Journal of Pharmaceutical Sciences|July 23, 2009
Kinetic assessment of luminal degradation of orally effective prodrugs for rational drug developmentTakashi Mizuma
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|September 15, 2009
Impact of intestinal metabolism on drug developmentTakashi Mizuma
Drug Metabolism and Pharmacokinetics|December 25, 2004
Kinetic impact of presystemic intestinal metabolism on drug absorption: experiment and data analysis for the prediction of in vivo absorption from in vitro dataTakashi Mizuma
International Journal of Pharmaceutics|June 3, 2009
Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10Takashi Mizuma
Journal of Pharmaceutical Sciences|April 3, 2008
Assessment of presystemic and systemic intestinal availability of orally administered drugs using in vitro and in vivo data in humans: intestinal sulfation metabolism impacts presystemic availability much more than systemic availability of salbutamol, SULT1A3 substrateTakashi Mizuma
Journal of Pharmaceutical Sciences|August 6, 2004
Dietary polyphenols (-)-epicatechin and chrysin inhibit intestinal glucuronidation metabolism to increase drug absorptionTakashi Mizuma, Shoji Awazu
Biological Procedures Online|May 8, 2003
The Metabolic Inhibition Model Which Predicts the Intestinal Absorbability and Metabolizability of Drug: Theory and ExperimentTakashi Mizuma, Shoji Awazu
The Journal of Pharmacy and Pharmacology|May 20, 2005
Kinetic characterization of glycosidase activity from disaccharide conjugate to monosaccharide conjugate in Caco-2 cellsTakashi Mizuma, Norihiko Fuseda, Masahiro Hayashi
Biological & Pharmaceutical Bulletin|November 6, 2003
Concentration-dependent atypical intestinal absorption of cyclic phenylalanylserine: small intestine acts as an interface between the body and ingested compoundsTakashi Mizuma, Takuo Narasaka, Shoji Awazu
The Journal of Pharmacy and Pharmacology|October 3, 2002
Uptake of cyclic dipeptide by PEPT1 in Caco-2 cells: phenolic hydroxyl group of substrate enhances affinity for PEPT1Takashi Mizuma, Takuo Narasaka, Shoji Awazu
Pageof 2